ICICI Securities has initiated coverage on Entero Healthcare with a 'Buy' rating, setting a target price of Rs 2,100. The brokerage points to the company’s strong margin expansion and successful acquisition strategy. While the company reported a 38.2% revenue growth in Q1 FY27, investors may want to track rising finance costs and the risks associated with integrating multiple acquisitions.
ICICI Securities has initiated coverage on Entero Healthcare, assigning a 'Buy' rating to the stock with a target price of Rs 2,100. The valuation is based on projected financial performance for fiscal year 2028, reflecting the brokerage's outlook on the company's ability to maintain its position within the fragmented Indian pharmaceutical distribution sector.
Financial Growth and Margin Expansion
The company has demonstrated strong growth in the first quarter of fiscal year 2027. Consolidated revenue reached Rs 1,940 crore, a 38.2% increase compared to the same period in the previous year. Profitability has also seen a significant boost, with net profit rising to Rs 52.05 crore, up from Rs 27.80 crore in Q1 FY26.
One of the primary reasons for the brokerage's positive stance is the company’s operating efficiency. Entero Healthcare’s EBITDA margin improved to 5.2% during the June 2026 quarter, compared to 4.0% in the same quarter last year. This margin profile is often higher than that of traditional industry peers, who typically operate within the 2% to 3% range. Furthermore, the company is expanding into the medical devices market, a move intended to diversify revenue and improve the working capital cycle.
Acquisition Strategy and Integration Risks
Entero Healthcare’s rapid expansion is largely driven by an aggressive acquisition strategy. Over the past four years, the firm has completed 22 acquisitions, which are expected to account for a significant portion of its total revenue. By acquiring smaller distributors, the company has managed to scale its operations quickly, placing it among the top three distributors of healthcare products in India.
However, this growth model carries specific financial and operational risks. As the company uses debt to fund these acquisitions, its finance costs have increased, rising to Rs 18.1 crore in Q1 FY27 from Rs 8.3 crore in the year-ago period. Investors may monitor how the company manages this rising debt servicing cost as it continues to expand.
Additionally, the success of this strategy relies heavily on the effective integration of the acquired companies. If these subsidiaries underperform, it could negatively impact consolidated profitability. The company faces stiff competition in the pharmaceutical distribution space, and its ability to sustain margins while managing its expanding debt load will be a key factor to watch in the coming quarters.